Most Read Articles
Pearl Toh, 20 Jul 2018
Women with pre-eclampsia or gestational hypertension during their first pregnancy had an increased risk of developing chronic hypertension, type 2 diabetes (T2D), and hypercholesterolaemia than those who were normotensive during pregnancy, according to a study. The risk persisted for several decades later, signalling these hypertensive disorders of pregnancy (HDP) as red flags for cardiovascular (CV) health for life.
Roshini Claire Anthony, 30 Jul 2018

Canagliflozin may provide a renoprotective effect in individuals with type 2 diabetes (T2D) and a history of cardiovascular disease (CVD), according to results from the CANVAS* Program.

Stephen Padilla, 31 Jul 2018
Patients with type 2 diabetes (T2D) treated with sulphonylureas as second-line drugs are at an increased risk of myocardial infarction (MI), all-cause mortality and severe hypoglycaemia compared with those who remained on metformin monotherapy, a recent study has found.
22 Jul 2018
There appears to be a nonlinear relationship between total oestradiol and free oestradiol and all-cause mortality among older men, according to data from the Three-City cohort study. Specifically, the association is stronger for cardiovascular disease mortality and nonexistent for cancer mortality.

Synthetic androgen shows promise as male birth control pill

Pearl Toh
20 Apr 2018

The investigational oral synthetic androgen dimethandrolone undecanoate (DMAU) suppresses serum testosterone levels to near castrate levels and appears safe when taken once daily for a month, showing potential as a male contraceptive pill, according to a study.

“DMAU is a major step forward in the development of a once-daily ‘male pill’,” said study senior investigator Professor Stephanie Page of the University of Washington in Seattle, Washington, US. “Many men say they would prefer a daily pill as a reversible contraceptive, rather than long-acting injections or topical gels, which are also in development.”

The double-blind study involved 100 healthy men (aged 18–50 years) who were randomized to placebo or oral DMAU (100, 200, or 400 mg) formulated in castor oil/benzyl benzoate or powder in capsule and taken once daily with food. [ENDO 2018, OR15-2]

Pharmacokinetic study revealed that serum concentrations of both dimethandrolone (DMA) and DMAU (p<0.001 for both) showed a dose-response relationship at 28 days.  

All active treatment groups saw their serum testosterone levels dropped to the hypogonadal range by day 28 (median, 13.4 ng/dL), regardless of doses or formulations.

Also, both hormones required for sperm production—the follicle-stimulating and luteinizing hormones—were suppressed to <1 IU/L in all participants in the 400-mg group (except one receiving 400 mg castor oil formulation).   

The low hormones levels, according to Page, were consistent with effective male contraception demonstrated in previous longer-term studies.

“Despite having low levels of circulating testosterone, very few subjects reported symptoms consistent with testosterone deficiency or excess,” she said.

There were no significant changes in vital signs or EKG. Nor were there significant changes in mood (p=0.68) or sexual function monitored prospectively by questionnaires. Nine participants reported decreased libido, of which eight were on DMAU and one received placebo.

No serious adverse events were reported.

However, HDL-C levels decreased by a median range of 7–17 mg/dL, hematocrit increased by a median of 0.2–2 percent, and weight increased by a median of 1.5–3.9 kg with DMAU treatment.

Also, acne occurred in eight participants—five from the DMAU and three from the placebo groups.

Nonetheless, all adverse events resolved by study conclusion.

According to Page, previous developments of male contraceptive pills were hampered by short half-life of the drug and side effect such as liver inflammation. In the current study, all participants passed safety tests for liver and kidney function.

“Daily oral administration with food of DMAU for 28 days in young healthy men is well tolerated … [and] suppresses serum testosterone to near castrate levels,” said Page. “These promising results are unprecedented in the development of a prototype male pill … [and] support further development of DMAU as a single agent oral male contraceptive pill.”

“Longer term studies are currently under way to confirm that DMAU taken every day blocks sperm production,” she added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 20 Jul 2018
Women with pre-eclampsia or gestational hypertension during their first pregnancy had an increased risk of developing chronic hypertension, type 2 diabetes (T2D), and hypercholesterolaemia than those who were normotensive during pregnancy, according to a study. The risk persisted for several decades later, signalling these hypertensive disorders of pregnancy (HDP) as red flags for cardiovascular (CV) health for life.
Roshini Claire Anthony, 30 Jul 2018

Canagliflozin may provide a renoprotective effect in individuals with type 2 diabetes (T2D) and a history of cardiovascular disease (CVD), according to results from the CANVAS* Program.

Stephen Padilla, 31 Jul 2018
Patients with type 2 diabetes (T2D) treated with sulphonylureas as second-line drugs are at an increased risk of myocardial infarction (MI), all-cause mortality and severe hypoglycaemia compared with those who remained on metformin monotherapy, a recent study has found.
22 Jul 2018
There appears to be a nonlinear relationship between total oestradiol and free oestradiol and all-cause mortality among older men, according to data from the Three-City cohort study. Specifically, the association is stronger for cardiovascular disease mortality and nonexistent for cancer mortality.